Lyra Therapeutics (LYRA) EBT Margin (2021 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly EBT Margin of 99271.43% in Q4 2025, down 314.94% on a QoQ basis from 23924.0% in Q3 2025, and down 9402119.0% YoY from N/an in Q4 2024.
Lyra Therapeutics (LYRA) EBT Margin (2021 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported EBT Margin for 5 consecutive years, with 99271.43% the latest figure, recorded in Q4 2025.
- EBT Margin for Q4 2025 came in at 99271.43%, down 9402119.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 7263.32% (down 117492.0% YoY), and the FY2025 annual result was 7263.32%, down 117492.0% from the prior year.
- EBT Margin for Q4 2025 stood at 99271.43%, down from 23924.0% in the prior quarter.
- The five-year high for EBT Margin was 2545.09% in Q1 2022, with the low at 129290.91% in Q4 2022.
- A 5-year average of 23642.68% and a median of 4859.98% in 2021 frame the typical range for EBT Margin.
- Across the five-year window, EBT Margin slumped 12423925 bps in 2022 and soared 11892173 bps in 2023, its largest moves.
- Lyra Therapeutics' EBT Margin stood at 5051.66% in 2021, then sank by 2459 bps to 129290.91% in 2022, then jumped by 92 bps to 10369.18% in 2023, then jumped by 49 bps to 5250.24% in 2024, then slumped by 1791 bps to 99271.43% in 2025.
- The last three EBT Margin figures came in at 99271.43% (Q4 2025), 23924.0% (Q3 2025), and 4062.84% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 12.09% |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | -99,271.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -99,271.43% |
| Sep 30, 2025 | -23,924.00% |
| Jun 30, 2025 | -4,062.84% |
| Mar 31, 2025 | -4,668.31% |
| Dec 31, 2024 | -5,250.24% |
| Sep 30, 2024 | -6,085.13% |
| Jun 30, 2024 | -8,046.66% |
| Mar 31, 2024 | -4,217.67% |
| Dec 31, 2023 | -10,369.18% |
| Sep 30, 2023 | -2,874.08% |
| Jun 30, 2023 | -3,407.42% |
| Mar 31, 2023 | -3,961.22% |
| Dec 31, 2022 | -129,290.91% |
| Sep 30, 2022 | -4,113.09% |
| Jun 30, 2022 | -2,736.38% |
| Mar 31, 2022 | -2,545.09% |
| Dec 31, 2021 | -5,051.66% |
| Sep 30, 2021 | -105,692.86% |